Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Dovitinib|DRUG: Fulvestrant|DRUG: Dovitinib Placebo
Sponsor: Novartis Pharmaceuticals